Insights into COVID-19: Perspectives on Drug Remedies and Host Cell Responses

dc.contributor.authorAwad Ahmed M.
dc.contributor.authorHansen Kamryn
dc.contributor.authorDel Rio Diana
dc.contributor.authorFlores Derek
dc.contributor.authorBarghash Reham F.
dc.contributor.authorKakkola Laura
dc.contributor.authorJulkunen Ilkka
dc.contributor.authorAwad Kareem
dc.contributor.organizationfi=InFLAMES Lippulaiva|en=InFLAMES Flagship|
dc.contributor.organizationfi=biolääketieteen laitos|en=Institute of Biomedicine|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organization-code1.2.246.10.2458963.20.68445910604
dc.contributor.organization-code1.2.246.10.2458963.20.77952289591
dc.converis.publication-id181911781
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/181911781
dc.date.accessioned2025-08-28T01:44:30Z
dc.date.available2025-08-28T01:44:30Z
dc.description.abstract<p>In light of the COVID-19 global pandemic caused by SARS-CoV-2, ongoing research has centered on minimizing viral spread either by stopping viral entry or inhibiting viral replication. Repurposing antiviral drugs, typically nucleoside analogs, has proven successful at inhibiting virus replication. This review summarizes current information regarding coronavirus classification and characterization and presents the broad clinical consequences of SARS-CoV-2 activation of the angiotensin-converting enzyme 2 (ACE2) receptor expressed in different human cell types. It provides publicly available knowledge on the chemical nature of proposed therapeutics and their target biomolecules to assist in the identification of potentially new drugs for the treatment of SARS-CoV-2 infection. <br></p>
dc.identifier.eissn2218-273X
dc.identifier.jour-issn2218-273X
dc.identifier.olddbid207990
dc.identifier.oldhandle10024/191017
dc.identifier.urihttps://www.utupub.fi/handle/11111/57386
dc.identifier.urlhttps://www.mdpi.com/2218-273X/13/10/1452
dc.identifier.urnURN:NBN:fi-fe2025082791844
dc.language.isoen
dc.okm.affiliatedauthorKakkola, Laura
dc.okm.affiliatedauthorJulkunen, Ilkka
dc.okm.affiliatedauthorAwad, Kareem
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline1182 Biochemistry, cell and molecular biologyen_GB
dc.okm.discipline3111 Biomedicineen_GB
dc.okm.discipline317 Pharmacyen_GB
dc.okm.discipline1182 Biokemia, solu- ja molekyylibiologiafi_FI
dc.okm.discipline3111 Biolääketieteetfi_FI
dc.okm.discipline317 Farmasiafi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA2 Scientific Article
dc.publisherFrontiers MDPI
dc.publisher.countrySwitzerlanden_GB
dc.publisher.countrySveitsifi_FI
dc.publisher.country-codeCH
dc.publisher.placeSwitzerland
dc.relation.articlenumber1452
dc.relation.doi10.3390/biom13101452
dc.relation.ispartofjournalBiomolecules
dc.relation.issue10
dc.relation.volume13
dc.source.identifierhttps://www.utupub.fi/handle/10024/191017
dc.titleInsights into COVID-19: Perspectives on Drug Remedies and Host Cell Responses
dc.year.issued2023

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
biomolecules-13-01452.pdf
Size:
1.81 MB
Format:
Adobe Portable Document Format